Trapping Cancers as They Adapt to Survive

Cancer Discovery
Rizwan Haq

Abstract

<b/> The evolution of cancer cells limits the efficacy of nearly all treatments for patients with solid tumors. Characterizing how cancers adapt to treatment could therefore lead to approaches that overcome resistance to therapy. In this issue of Cancer Discovery, Song and colleagues describe the evolution of melanomas upon exposure to BRAF inhibitors, demonstrating that adaptive changes in the tumor create a vulnerability that can be targeted with immune checkpoint inhibitors. Cancer Discov; 7(11); 1216-7. ©2017 AACR.See related article by Song et al., p. 1248.

References

Feb 27, 2001·Nature Immunology·Y LatchmanG J Freeman
Jan 29, 2008·Blood·Takeshi AzumaLieping Chen
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Apr 5, 2013·The New England Journal of Medicine·Antoni RibasJedd Wolchok
Apr 30, 2014·The Journal of Experimental Medicine·Muhammad Zaeem NomanSalem Chouaib
Apr 5, 2017·Nature Reviews. Clinical Oncology·Jason J LukeGeorgina V Long
Jun 18, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jennifer H YearleyTerrill McClanahan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.